来宝网移动站

Decitabine(地西他滨)大量现货促销

来宝网 2010/12/30点击2188次

 

上海浩然生物订购电话:021-51870956

在线QQ:470003480

中文名:地西他滨;5-氮杂-2’-脱氧胞嘧啶核苷

英文名: 5-Aza-2′-deoxycytidine; 2′-Deoxy-5-azacytidineDecitabine

CAS:2353-33-5

产品作用

地西他滨作为特异的 DNA甲基化转移酶抑制剂,可逆转 DNA的甲基化过程,诱导肿瘤细胞向正常细胞分化或诱导肿瘤细胞凋亡。在肿瘤细胞内,地西他滨被脱氧胞苷激酶磷酸化,以磷酸盐的形式与 DNA掺合。高浓度的地西他滨掺合可抑制 DNA合成诱导细胞死亡,发挥其细胞毒作用;低浓度的地西他滨掺合可替代肿瘤细胞内的胞嘧啶与 DNA甲基化转移酶共价结合,使 DNA甲基化转移酶失活但不会导致细胞死亡。

地西他滨的适应证为骨髓增生异常综合征,另有研究,其对镰状细胞性贫血、髓性细胞白血病以及一些实体瘤也有疗效。

外观为:白色或类白色结晶粉末

 

SIGMA相关资料:

Sigma A3656  5-Aza-2′-deoxycytidine

≥97%

Synonym:

2′-Deoxy-5-azacytidine'' Decitabine'' 4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1''3''5-triazin-2(1H)-one

CAS Number:

2353-33-5

Linear Formula:

C8H12N4O4

Molecular Weight:

228.21

Beilstein Registry Number:

617982

EC Number:

219-089-4

MDL number:

MFCD00043011

PubChem Substance ID:

24890797

 

Description

Frequently Asked Questions

Live Chat and Frequently Asked Questions are available for this Product.

General description

Decitabine is an epigenetic modifier that inhibits DNA methyltransferase activity which results in DNA demethylation (hypomethylation) and gene activation by remodeling “opening” chromatin. Genes are synergistically reactivated when demethylation is combined with histone hyperacetylation.

Biochem/physiol Actions

5′-Azadeoxycytidine causes DNA demethylation or hemi-demethylation. DNA demethylation can regulate gene expression by "opening" the chromatin structure detectable as increased nuclease sensitivity. This remodeling of chromatin structure allows transcription factors to bind to the promoter regions'' assembly of the transcription complex'' and gene expression.

 

性质

assay

≥97%

solubility

acetic acid: water (1:1): 50 mg/mL

 

安全性

Personal Protective Equipment

dust mask type N95 (US)'' Eyeshields'' Gloves

Hazard Codes

Xn

Risk Statements

22-36/37/38

Safety Statements

26

WGK Germany

3

RTECS

XZ3012000

 

品名

产地

货号

规格

单价

备注

地西他滨  Decitabine

Sigma

A3656

5MG

询价

现货

地西他滨  Decitabine

Sigma

A3656

10MG

询价

现货

 

推荐仪器
  • *
  • *
  • *
  • *